Drug interactions
Empagliflozin-linagliptin + Paclitaxel protein bound
Severity: Minor
Empagliflozin-linagliptin and Paclitaxel protein bound: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Paclitaxel is a CYP3A4 substrate and not a recognised inducer, so a meaningful change in linagliptin exposure is not expected. Any glycemic change during chemotherapy is more likely due to the illness, steroids or other supportive drugs.
What this interaction means in plain words
Empagliflozin-linagliptin and Paclitaxel protein bound have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
No established pharmacokinetic mechanism; a minor competitive effect at CYP3A4 is only theoretical.
What to do
No specific action required; monitor blood glucose as part of routine oncology care.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Empagliflozin-linagliptin and Paclitaxel protein bound, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Empagliflozin-linagliptin
Frequently asked questions
Can I take Empagliflozin-linagliptin with Paclitaxel protein bound?
MediHelp rates the interaction as minor. Empagliflozin-linagliptin and Paclitaxel protein bound have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Paclitaxel is a CYP3A4 substrate and not a recognised inducer, so a meaningful change in linagliptin exposure is not expected. Any glycemic change during chemotherapy is more likely due to the illness, steroids or other supportive drugs.
How serious is the interaction between Empagliflozin-linagliptin and Paclitaxel protein bound?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No specific action required; monitor blood glucose as part of routine oncology care.
What other medicines interact with Empagliflozin-linagliptin?
MediHelp also lists interactions of Empagliflozin-linagliptin with, for example, Fosphenytoin, Rifampin, Rifapentine. The full list is on the Empagliflozin-linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
